Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e82154
I. Petrov, A. Cherneva, S. Vasilev, Y. Gecov, Z. Stankov
Mitral regurgitation or mitral insuffi ciency is the second most common valve pathology requiring a surgical treatment worldwide. It is characterized by an abnormal return of blood from the left ventricle to the left atrium during the systole. The incidence of mitral regurgitation increases in line with the rise in the life expectancy and the overall aging of the world population. According to the pathoanatomy and the mechanism of development, there are two main types of mitral regurgitation: a primary (degenerative) regurgitation and secondary (functional) regurgitation. In the fi rst type, there is organic damage to the valve and/or the valve apparatus, and in the second type, there is a secondary dysfunction of the mitral valve due to damage to the structure and/or the function of the left ventricle. The treatment of choice for the management of the mitral regurgitation is a surgical intervention. In recent years new high-tech transcatheter methods of treatment have been introduced in clinical practice. The most popular and proven method of treatment in patients who could not undergo classic cardiac surgery is the MitraClip edge-to-edge transcatheter approximation system. Other endovascular methods of treatment are percutaneous plasty device Pascal (Edwards Lifesciences) and Cardioband using transseptal approach, and also NeoChord and Harpoon using transapical approach.
{"title":"Overview of the catheter-based methods for treatment of mitralregurgitation","authors":"I. Petrov, A. Cherneva, S. Vasilev, Y. Gecov, Z. Stankov","doi":"10.3897/bgcardio.28.e82154","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e82154","url":null,"abstract":"Mitral regurgitation or mitral insuffi ciency is the second most common valve pathology requiring a surgical treatment worldwide. It is characterized by an abnormal return of blood from the left ventricle to the left atrium during the systole. The incidence of mitral regurgitation increases in line with the rise in the life expectancy and the overall aging of the world population. According to the pathoanatomy and the mechanism of development, there are two main types of mitral regurgitation: a primary (degenerative) regurgitation and secondary (functional) regurgitation. In the fi rst type, there is organic damage to the valve and/or the valve apparatus, and in the second type, there is a secondary dysfunction of the mitral valve due to damage to the structure and/or the function of the left ventricle. The treatment of choice for the management of the mitral regurgitation is a surgical intervention. In recent years new high-tech transcatheter methods of treatment have been introduced in clinical practice. The most popular and proven method of treatment in patients who could not undergo classic cardiac surgery is the MitraClip edge-to-edge transcatheter approximation system. Other endovascular methods of treatment are percutaneous plasty device Pascal (Edwards Lifesciences) and Cardioband using transseptal approach, and also NeoChord and Harpoon using transapical approach.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49330618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e82140
P. Polomski, Z. Stankov, I. Petrov, Z. Stoykova
The frequency of TAVI procedures worldwide is progressively increasing. The age of patients applying for TAVI is also declining, as a result of which life expectancy is increasing. Atherosclerotic disease (including ischemic heart disease) and aortic stenosis share some common risk factors and pathogenesis, which explains the frequent combination of diseases in the same patient. We present a clinical case of successful percutaneous coronary intervention in a patient presenting with acute coronary syndrome with a previously implanted TAVI prosthesis.
{"title":"Clinical case of endovascular coronary revascularization after TAVI","authors":"P. Polomski, Z. Stankov, I. Petrov, Z. Stoykova","doi":"10.3897/bgcardio.28.e82140","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e82140","url":null,"abstract":"The frequency of TAVI procedures worldwide is progressively increasing. The age of patients applying for TAVI is also declining, as a result of which life expectancy is increasing. Atherosclerotic disease (including ischemic heart disease) and aortic stenosis share some common risk factors and pathogenesis, which explains the frequent combination of diseases in the same patient. We present a clinical case of successful percutaneous coronary intervention in a patient presenting with acute coronary syndrome with a previously implanted TAVI prosthesis.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46140456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e83164
H. Angelov, P. Simeonov, P. Krastev, F. Abedinov, J. Jorgova, D. Trendafilova
Transcutaneous aortic valve implantation has been established as an effective method for the treatment of highgrade aortic stenosis in non-operative, high-risk for conventional surgery patients. According to the developed implantation technologies, the prostheses are divided into balloon-expandable valve prostheses (balloon-expandable valves, BEV) and self-expanding valve prostheses (self-expanding prostheses SEV). The two types of devices have different models for implantation, stratum architecture, cusps characteristics, leading to different hemodynamics, frequency of use and performance of normal prosthesis function. The research aims to monitor the short-term results, up to 1 month after discharge, in terms of mortality, the manifestation of heart failure, (para) prosthetic regurgitation, implantation of a pacemaker, and vascular complications. Materials and methods: the article presents a retrospective follow-up of a total of 230 high-risk for conventional cardiac surgery patients with high-grade aortic stenosis treated in a cardiology clinic at UMHAT St. Ekaterina Sofia until 2020, divided into two groups depending on the implanted type of prosthesis. Conclusions: The results obtained based on our experience prove the safety of new prostheses. When choosing between BEV and SEV, the best clinical outcome requires a good knowledge of the strengths and weaknesses of using medical devices with a personalized approach consistent with the clinical and anatomical characteristics of the patient.
{"title":"Balloon expandable vs. self-expandable transcatheter aortic valve prosthesis short-term results of retrospective study","authors":"H. Angelov, P. Simeonov, P. Krastev, F. Abedinov, J. Jorgova, D. Trendafilova","doi":"10.3897/bgcardio.28.e83164","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e83164","url":null,"abstract":"Transcutaneous aortic valve implantation has been established as an effective method for the treatment of highgrade aortic stenosis in non-operative, high-risk for conventional surgery patients. According to the developed implantation technologies, the prostheses are divided into balloon-expandable valve prostheses (balloon-expandable valves, BEV) and self-expanding valve prostheses (self-expanding prostheses SEV). The two types of devices have different models for implantation, stratum architecture, cusps characteristics, leading to different hemodynamics, frequency of use and performance of normal prosthesis function. The research aims to monitor the short-term results, up to 1 month after discharge, in terms of mortality, the manifestation of heart failure, (para) prosthetic regurgitation, implantation of a pacemaker, and vascular complications. Materials and methods: the article presents a retrospective follow-up of a total of 230 high-risk for conventional cardiac surgery patients with high-grade aortic stenosis treated in a cardiology clinic at UMHAT St. Ekaterina Sofia until 2020, divided into two groups depending on the implanted type of prosthesis. Conclusions: The results obtained based on our experience prove the safety of new prostheses. When choosing between BEV and SEV, the best clinical outcome requires a good knowledge of the strengths and weaknesses of using medical devices with a personalized approach consistent with the clinical and anatomical characteristics of the patient.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48815583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e82135
P. Polomski, Z. Stankov, I. Petrov, I. Tasheva, G. Dobrev
Balloon valvuloplasty of the aortic valve (BAV) in aortic stenosis has been practiced for over 35 years. The initial enthusiasm caused by the excellent immediate hemodynamic effect of the procedure disappears due to the rapid restenosis of the aortic valve after intervention. The results of modern methods for defi nitive treatment of aortic valve stenosis – AVR and TAVI are excellent, thanks to which they are fi rmly rooted in treatment guidelines. However, BAV has its indications in symptomatic patients who are not suitable for defi nitive interventions. This publication discusses current indications for BAV, the main stages of the procedure, possible complications, and treatment outcomes.
{"title":"Balloon aortic valvuloplasty in degenerative aortic stenosis","authors":"P. Polomski, Z. Stankov, I. Petrov, I. Tasheva, G. Dobrev","doi":"10.3897/bgcardio.28.e82135","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e82135","url":null,"abstract":"Balloon valvuloplasty of the aortic valve (BAV) in aortic stenosis has been practiced for over 35 years. The initial enthusiasm caused by the excellent immediate hemodynamic effect of the procedure disappears due to the rapid restenosis of the aortic valve after intervention. The results of modern methods for defi nitive treatment of aortic valve stenosis – AVR and TAVI are excellent, thanks to which they are fi rmly rooted in treatment guidelines. However, BAV has its indications in symptomatic patients who are not suitable for defi nitive interventions. This publication discusses current indications for BAV, the main stages of the procedure, possible complications, and treatment outcomes.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70395778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e82274
I. Petrov, Z. Stankov, P. Polomski, J. Stoykova, A. Cherneva, D. Boychev, M. Bonev
Since the first procedure in humans in 2002, transcatheter aortic valve implantation (TAVI) has evolved from innovative procedure of the future to treatment of choice in high-risk patients with potential to become a routine procedure in the near future. Thanks to the excellent safety profile, the emerging evidence from clinical trials, TAVI has raised its class of recommendation in the guidelines. The constantly upraising frequency of TAVI and the experience gained have led to the need of procedure improvement and standardization. Between 2013 and 2021 208 patients underwent TAVI in our cardiovascular center. The standard approach was used for 141 of them and the minimalistic and precise approach for the rest 67 patients. The main focus of this manuscript is improvement of the procedure results, quality of life and comfort of the patients, while providing a better pharmacoeconomic profile.The minimalistic and precise protocol of implantation and the vascular device closure are thoroughly described. The safety and the efficiency of the minimalistic and precise approach compared to the standard one, which is considered the ”gold standard” are proven. At the same time the minimalistic approach is described as superior to the standard one in using the radial artery as second vascular approach to reduce vascular complications and bleeding. Other advantage of the minimalistic approach is the implantation of the transcatheter aortic valve in position 0/1 while using rapid pacing, to reduce the frequency of pacemaker implantation, reduction of paravalvular leak and reduction of hospital stay. TAVI has proved to be an alternative to surgical aortic valve replacement in high risk patients and in the past years also in intermediate and low risk patients. In order TAVI to become a PCI-like procedure it must be simplified. That is exactly why the minimalistic and precise approach for TAVI is needed and it is the future of the procedure.
{"title":"Safety and efficiency of the minimalistic and precise approachfor transcatheter aortic valve implantation (TAVI) comparedto the standard one","authors":"I. Petrov, Z. Stankov, P. Polomski, J. Stoykova, A. Cherneva, D. Boychev, M. Bonev","doi":"10.3897/bgcardio.28.e82274","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e82274","url":null,"abstract":"Since the first procedure in humans in 2002, transcatheter aortic valve implantation (TAVI) has evolved from innovative procedure of the future to treatment of choice in high-risk patients with potential to become a routine procedure in the near future. Thanks to the excellent safety profile, the emerging evidence from clinical trials, TAVI has raised its class of recommendation in the guidelines. The constantly upraising frequency of TAVI and the experience gained have led to the need of procedure improvement and standardization. Between 2013 and 2021 208 patients underwent TAVI in our cardiovascular center. The standard approach was used for 141 of them and the minimalistic and precise approach for the rest 67 patients. The main focus of this manuscript is improvement of the procedure results, quality of life and comfort of the patients, while providing a better pharmacoeconomic profile.The minimalistic and precise protocol of implantation and the vascular device closure are thoroughly described. The safety and the efficiency of the minimalistic and precise approach compared to the standard one, which is considered the ”gold standard” are proven. At the same time the minimalistic approach is described as superior to the standard one in using the radial artery as second vascular approach to reduce vascular complications and bleeding. Other advantage of the minimalistic approach is the implantation of the transcatheter aortic valve in position 0/1 while using rapid pacing, to reduce the frequency of pacemaker implantation, reduction of paravalvular leak and reduction of hospital stay. TAVI has proved to be an alternative to surgical aortic valve replacement in high risk patients and in the past years also in intermediate and low risk patients. In order TAVI to become a PCI-like procedure it must be simplified. That is exactly why the minimalistic and precise approach for TAVI is needed and it is the future of the procedure.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70395798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e83660
A. Popova, D. Trendafilova, J. Jorgova, D. Petkov, F. Abedinov, T. Hristova, Stanislav Ivanov
We report a case of an 80-years–old patient with a severe, symptomatic aortic valve stenosis and history of ischemic heart disease, previously treated by coronary artery bypass graft surgery. The patient was contraindicated for conventional surgical aortic valve replacement (SAVR) due to advanced age and underlying comorbidity, therefore transcatheter aortic valve implantation (TAVI) has been offered. The access options for the procedure were restricted by the underlying generalized atherosclerosis process causing peripheral vessel disease. We have chosen transaortic access for the patient which in that case was the only possible option. The transaortic valve implantation was successful with satisfactory hemodynamic results, improvement in functional class heart failure of the patient and preserving the function and anatomy of the coronary artery bypass graft. This case report demonstrates that the lack of favorable transfemoral access for TAVI should not be a limitation by itself for the procedure, rather than be stimulus for searching and using new and alternative access for it.
{"title":"Transcatheter aortic valve implantation via transaortic surgical access","authors":"A. Popova, D. Trendafilova, J. Jorgova, D. Petkov, F. Abedinov, T. Hristova, Stanislav Ivanov","doi":"10.3897/bgcardio.28.e83660","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e83660","url":null,"abstract":"We report a case of an 80-years–old patient with a severe, symptomatic aortic valve stenosis and history of ischemic heart disease, previously treated by coronary artery bypass graft surgery. The patient was contraindicated for conventional surgical aortic valve replacement (SAVR) due to advanced age and underlying comorbidity, therefore transcatheter aortic valve implantation (TAVI) has been offered. The access options for the procedure were restricted by the underlying generalized atherosclerosis process causing peripheral vessel disease. We have chosen transaortic access for the patient which in that case was the only possible option. The transaortic valve implantation was successful with satisfactory hemodynamic results, improvement in functional class heart failure of the patient and preserving the function and anatomy of the coronary artery bypass graft. This case report demonstrates that the lack of favorable transfemoral access for TAVI should not be a limitation by itself for the procedure, rather than be stimulus for searching and using new and alternative access for it.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42721126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e79582
H. Baychev, E. Kostadinova, A. Partenova, K. Genova, T. Shalganov
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a syndrome of diverse etiology and unclear pathogenesis, with an incidence of 5-15% and varying prognosis. Cardiac magnetic resonance imaging (MRI) is playing an increasing role in the diagnosis of MINOCA and in distinguishing the causes that led to it, while being at the same time an important predictor of prognosis in these patients. We present a 40-year-old man with clinical, laboratory and instrumental data for acute coronary syndrome complicated by acute heart failure. The invasive assessment ruled out obstructive coronary heart disease as well as Takotsubo cardiomyopathy. MINOCA and myocarditis were discussed in the differential diagnostic plan. To differentiate them, cardiac MRI was performed, which confi rmed the diagnosis of „myocardial infarction with non-obstructive coronary arteries“.
{"title":"Magnetic resonance imaging of MINOCA in underlying non-ischemic dilated cardiomyopathy: a case report","authors":"H. Baychev, E. Kostadinova, A. Partenova, K. Genova, T. Shalganov","doi":"10.3897/bgcardio.28.e79582","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e79582","url":null,"abstract":"Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a syndrome of diverse etiology and unclear pathogenesis, with an incidence of 5-15% and varying prognosis. Cardiac magnetic resonance imaging (MRI) is playing an increasing role in the diagnosis of MINOCA and in distinguishing the causes that led to it, while being at the same time an important predictor of prognosis in these patients. We present a 40-year-old man with clinical, laboratory and instrumental data for acute coronary syndrome complicated by acute heart failure. The invasive assessment ruled out obstructive coronary heart disease as well as Takotsubo cardiomyopathy. MINOCA and myocarditis were discussed in the differential diagnostic plan. To differentiate them, cardiac MRI was performed, which confi rmed the diagnosis of „myocardial infarction with non-obstructive coronary arteries“.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70395406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e82418
I. Dimitrova, J. Jorgova, P. Simeonov, H. Angelov, D. Trendafilova
Transcatheter aortic valve implantation (TAVI) is an established choice for the treatment of severe aortic stenosis (AS) in patients who are deemed inoperable or at high surgical risk. There are limited data for the safety and effi cacy of the method in patients with bicuspid aortic valve (BAV), the most common congenital valve defect. Patients with BAV were excluded from randomized clinical trials (RCTs), comparing TAVI to surgery due to the heterogeneous anatomy of this nosological unit and concerns about unsatisfactory procedural and clinical outcomes after TAVI. With the improvement of the design of the new generations devices, with the growing technical experience of the teams and the progress in the imaging techniques, better results and fewer complications are observed, which could be a prerequisite for expanding the indications for TAVI in patients with BAV. This review presents TAVI treatment options for patients with BAV, the results of available registers in terms of safety and effi cacy of the procedure, and future perspectives.
{"title":"TAVI in bicuspid aortic valve","authors":"I. Dimitrova, J. Jorgova, P. Simeonov, H. Angelov, D. Trendafilova","doi":"10.3897/bgcardio.28.e82418","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e82418","url":null,"abstract":"Transcatheter aortic valve implantation (TAVI) is an established choice for the treatment of severe aortic stenosis (AS) in patients who are deemed inoperable or at high surgical risk. There are limited data for the safety and effi cacy of the method in patients with bicuspid aortic valve (BAV), the most common congenital valve defect. Patients with BAV were excluded from randomized clinical trials (RCTs), comparing TAVI to surgery due to the heterogeneous anatomy of this nosological unit and concerns about unsatisfactory procedural and clinical outcomes after TAVI. With the improvement of the design of the new generations devices, with the growing technical experience of the teams and the progress in the imaging techniques, better results and fewer complications are observed, which could be a prerequisite for expanding the indications for TAVI in patients with BAV. This review presents TAVI treatment options for patients with BAV, the results of available registers in terms of safety and effi cacy of the procedure, and future perspectives.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70395438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-20DOI: 10.3897/bgcardio.28.e81189
M. Ivanov, M. Peneva, I. Ivanov, N. Gotcheva, L. Boyadzhiev
Right-sided endocarditis, and endocarditis of the tricuspid valve in particular, is a relatively uncommon condition, encountered in approximately 5 to 10 percent of all cases of infectious endocarditis (IE). The recent increase in the prevalence of right-sided IE is attributed to intravenous drug abuse as well as the increased utilization of implantable cardiac devices such as pacemakers, implantable cardioverter-defi brillators, and cardiac resynchronization therapy devices. These cases pose signifi cant therapeutic challenges, especially when right-sided devices are involved. We present a case of 45-year-old male patient with proven IE with involvement of the tricuspid valve and implantable cardiac device lead and demonstrate the results of an antibacterial treatment and surgical interventions carried out in two steps – explanation of the lead of the implantable cardiac device, excision of the tricuspid valve, and implantation of an epicardial implantable device; subsequent tricuspid valve replacement with mechanical valve, surgical revascularization, and fi nally replacement of the thrombosed mechanical valve with a biological valve. The optimal preoperative management and the following comprehensive surgical intervention resulted in resolution of IE as it has been demonstrated by the lack of recurrence of systemic infl ammatory response syndrome and no further hospitalisations due to cardiovascular events.
{"title":"Therapeutic options in the treatment of infectious endocarditis of an implantable cardiac device lead","authors":"M. Ivanov, M. Peneva, I. Ivanov, N. Gotcheva, L. Boyadzhiev","doi":"10.3897/bgcardio.28.e81189","DOIUrl":"https://doi.org/10.3897/bgcardio.28.e81189","url":null,"abstract":"Right-sided endocarditis, and endocarditis of the tricuspid valve in particular, is a relatively uncommon condition, encountered in approximately 5 to 10 percent of all cases of infectious endocarditis (IE). The recent increase in the prevalence of right-sided IE is attributed to intravenous drug abuse as well as the increased utilization of implantable cardiac devices such as pacemakers, implantable cardioverter-defi brillators, and cardiac resynchronization therapy devices. These cases pose signifi cant therapeutic challenges, especially when right-sided devices are involved. We present a case of 45-year-old male patient with proven IE with involvement of the tricuspid valve and implantable cardiac device lead and demonstrate the results of an antibacterial treatment and surgical interventions carried out in two steps – explanation of the lead of the implantable cardiac device, excision of the tricuspid valve, and implantation of an epicardial implantable device; subsequent tricuspid valve replacement with mechanical valve, surgical revascularization, and fi nally replacement of the thrombosed mechanical valve with a biological valve. The optimal preoperative management and the following comprehensive surgical intervention resulted in resolution of IE as it has been demonstrated by the lack of recurrence of systemic infl ammatory response syndrome and no further hospitalisations due to cardiovascular events.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42258742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：